MP-AzeFlu在罗马尼亚真实世界中快速有效控制过敏性鼻炎
该多中心前瞻性非干预研究纳入253例11岁以上中重度过敏性鼻炎患者,处方MP-AzeFlu鼻喷剂后用VAS在0、1、3、7、14天评估症状。VAS均值从基线78.4 mm降至末日14.7 mm,83.4%患者达到良好控制切点,95.2%在第3天自认良好或部分控制。
要点
- MP-AzeFlu使VAS均值从基线78.4 mm降至末日14.7 mm。
- 83.4%患者末日达到小于39 mm的良好控制VAS切点。
- 疗效不受疾病严重度、表型或年龄影响。
核心结论
- MP-AzeFlu在罗马尼亚真实世界中对中重度过敏性鼻炎提供快速、有效且持续的症状控制。
研究设计与样本
- 多中心、前瞻性、非干预研究,纳入253例11岁以上中重度过敏性鼻炎患者。
主要发现
- VAS均值(标准差)从基线78.4(15.1)mm降至末日14.7(15.1)mm。
- 83.4%患者末日达到小于39 mm的良好控制VAS切点。
- 95.2%患者第3天自认症状良好或部分控制。
- 疗效不受疾病严重度、表型或患者年龄影响。
关键数值与推荐
- VAS评分范围0(完全不困扰)至100 mm(非常困扰)。
- 良好控制VAS切点为38 mm,研究按小于39 mm计算达标比例。
临床怎么用
- 可按ARIA与欧盟建议用VAS评估过敏性鼻炎控制水平并指导治疗决策。
- 中重度过敏性鼻炎可考虑MP-AzeFlu作为治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Allergic Rhinitis and its Impact on Asthma (ARIA) and the European Union (EU) recommend a shift to guide allergic rhinitis (AR) treatment decisions from symptom severity to disease control, using a simple visual analogue scale (VAS). Using this VAS we assessed, in a real-life study in Romania, the effectiveness of MP-AzeFlu nasal spray. METHODOLOGY: In this multi-centre, prospective, non-interventional study, 253 patients (over 11 years old) with moderate-to-severe AR were prescribed MP-AzeFlu and assessed their symptoms on a VAS (0 (not at all bothersome) to 100 mm (very bothersome)) on Days 0, 1, 3, 7 and 14. The proportion of patients who achieved a defined VAS score cut-off for well-controlled (38 mm) AR were also calculated. Patients perception of disease control was assessed on Day 3. RESULTS: MP-AzeFlu use was associated with a mean (standard deviation) VAS score reduction from 78.4 (15.1) mm at baseline to 14.7 (15.1) mm on the last day. Effectiveness was consistent irrespective of disease severity, phenotype or patient age. 83.4% of patients achieved the smaller than 39 mm well-controlled VAS score cut-off by last day and 95.2% considered their symptoms to be well- or partly controlled at Day 3. CONCLUSIONS: MP-AzeFlu provided rapid, effective and sustained AR symptom control in a real-life setting in Romania, irrespective of severity, phenotype or patient age, aligning with ARIA and EU recommendations and supporting the position of MP-AzeFlu as the drug of choice for the treatment of moderate-to-severe AR.
引用
- Agache I, Doros IC, Leru PM, et al. MP-AzeFlu provides rapid and effective allergic rhinitis control: results of a non-interventional study in Romania. Rhinology. 2018. PMID: 28942457. doi:10.4193/Rhin16.278
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。